Denise Scots-Knight - Jun 25, 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Executive Officer, Director
Signature
/s/ Christine Fox, by power of attorney
Stock symbol
MREO
Transactions as of
Jun 25, 2024
Transactions value $
-$463,487
Form type
4
Date filed
6/27/2024, 04:15 PM
Previous filing
Jun 25, 2024
Next filing
Sep 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MREO American Depositary Shares representing Ordinary Shares Sale -$150K -40.7K -4.83% $3.69 802K Jun 25, 2024 Direct F1, F2, F3, F4, F6
transaction MREO American Depositary Shares representing Ordinary Shares Sale -$313K -92.3K -11.51% $3.39 710K Jun 26, 2024 Direct F1, F3, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer.
F3 Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4 The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4.
F5 The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive.
F6 Includes 1,200 ADSs jointly owned by Reporting person and her spouse.